PubMed Journals Articles About "Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014" RSS

12:49 EDT 23rd March 2018 | BioPortfolio

Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 articles that have been published worldwide.

More Information about "Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014" on BioPortfolio

We have published hundreds of Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 news stories on BioPortfolio along with dozens of Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 Clinical Trials and PubMed Articles about Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 Companies in our database. You can also find out about relevant Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014 Drugs and Medications on this site too.

Showing "Hyperphosphatemia Chronic Kidney Disease Pipeline Review 2014" PubMed Articles 1–25 of 42,000+

Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.

In this study, we coordinated a network meta-analysis to establish the efficacy and safety of different agents used in the treatment of hyperphosphatemia patients with chronic kidney disease.

Effect of Npt2b deletion on intestinal and renal inorganic phosphate (Pi) handling.

Hyperphosphatemia is common in chronic kidney disease and is associated with morbidity and mortality. The intestinal Na(+)-dependent phosphate transporter Npt2b is thought to be an important molecular target for the prevention of hyperphosphatemia. The role of Npt2b in the net absorption of inorganic phosphate (Pi), however, is controversial.

SES, Chronic Kidney Disease, and Race in the U.S.: A Systematic Review and Meta-analysis.

The risk of chronic kidney disease (CKD) in the U.S. is higher in individuals with low SES than in those with high SES. However, differences in these risks between African Americans and whites are unclear.

Urinary Fractional Excretion of Phosphorus in Dogs with Spontaneous Chronic Kidney Disease.

The increase of urinary fractional excretion of phosphorus (uFEP) may indicate phosphorus retention before the onset of hyperphosphatemia in the early stages of chronic kidney disease (CKD). The hypothesis of this study is whether uFEP may increase during the early stage of CKD as a compensatory mechanism to prevent hyperphosphatemia as well as whether hyperphosphatemia in the late stages is associated with increase or decrease in uFEP in dogs with naturally occurring CKD; therefore, the aim of this study w...

Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease.

Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic...

Chronic Kidney Disease - Update 2018.

SGLT2-INHIBITION IN DIABETIC AND NON-DIABETIC KIDNEY DISEASE:  The CANVAS Program Collaborative Group study confirmed nephroprotective actions by canagliflocin comparable to empagliflozin as published in the EMPA-REG Outcome study. Treatment with Liraglutide (LEADER study) also suggests nephroprotection via albuminuria reduction a decreased eGFR decline in subgroups and depending on stages of diabetic nephropathy. KDIGO CKD-MBD GUIDELINE UPDATE 2017:  In July 2017, an update of the KDIGO (Kidney Disease...

Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population.

Evidence indicates a role for dyslipidemia in the development of chronic kidney disease (CKD). However, the association of lipid abnormalities and their ratios with kidney disease using the new CKD Epidemiology Collaboration (CKD-EPI) equation is not well understood.

MicroRNAs as biomarkers in chronic kidney disease.

This review summarizes recent data supporting the concept that urinary microRNAs are a useful new class of biomarker. They may improve capacity to stratify patients with chronic kidney disease according to risk of progression, and may also inform about response to therapy.

Is acute kidney injury a harbinger for chronic kidney disease?

Despite abundant evidence in adults, the relationship between acute kidney injury (AKI) and chronic kidney disease (CKD) remains unanswered in pediatrics. Obstacles to overcome include the challenges defining these entities and the lack of long-term follow-up studies. This review focuses on pediatric populations at high-risk for AKI, the evidence of the long-term effect of AKI on renal health, and biomarkers to detect renal disease.

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease.

Ferric citrate has been reported to have the potential to reduce phosphate and increase iron availability in patients with chronic kidney disease. In the present study, we evaluated its safety and efficacy in phosphate reduction and iron supplementation in chronic kidney disease stage 3-5 requiring dialysis patients. We systematically searched for clinical trials published in PubMed, Medline, and Cochrane databases. Only randomized controlled trials on the effects of ferric citrate in chronic kidney disease...

Drug-Eluting vs Bare-Metal Stents in Patients With Chronic Kidney Disease and Coronary Artery Disease: Insights From a Systematic Review and Meta-Analysis.

Most drug-eluting stent (DES) trials have excluded patients with chronic kidney disease (CKD). The efficacy of DES implantation in patients with CKD is therefore not known.

Fracture risk and treatment in chronic kidney disease.

Chronic kidney disease (CKD) is associated with the development of mineral bone disorder (MBD), osteoporosis, and fragility fractures. The purpose of this review is to provide an update on recent findings in the diagnosis and treatment of osteoporosis in patients with CKD.

Hyaluronic Acid as a New Biomarker to Differentiate Acute Kidney Injury From Chronic Kidney Disease.

It may be difficult to differentiate acute kidney injury from chronic kidney disease in patients with no past medical reports of kidney function. This study aimed to investigate the role of serum hyaluronic acid (HA), which is known as a marker of fibrosis, in differential diagnosis of kidney failure.

Continuation of lithium after a diagnosis of chronic kidney disease.

To investigate whether continued lithium or anticonvulsant treatment after a first diagnosis of chronic kidney disease (CKD) was associated with progression to irreversible end-stage kidney disease.

Obesity and chronic kidney disease.

To review recent advances in the epidemiology, pathophysiology, clinical features, and treatment of obesity-related kidney disease.

Managing diabetic kidney disease.

Diabetes mellitus (DM) is the leading cause of chronic kidney disease (CKD). This review covers the pillars of care essential for the management of diabetic kidney disease (DKD) including (1) early diagnosis, (2) improved glycaemic control, (3) treatment of hypertension, (4) identification and treatment of associated metabolic bone disease and (5) identification and effective management of dyslipidaemia and additional cardiovascular risk factors.

Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD).

No studies have examined the association among serum hepcidin, iron indices, or anemia status based on the kidney function of non-dialysis chronic kidney disease (CKD) patients.

Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease.

Chronic kidney disease (CKD) is strongly associated with peripheral artery disease (PAD). Detection of subclinical PAD may allow early interventions for or prevention of PAD in persons with CKD. Whether the presence of atherosclerotic plaque and femoral intima-media thickness (IMT) are associated with kidney function is unknown.

How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit.

In the UK, primary care records are electronic and require doctors to ascribe disease codes to direct care plans and facilitate safe prescribing. We investigated factors associated with coding of chronic kidney disease (CKD) in patients with reduced kidney function and the impact this has on patient management.

Epidemiology of acute kidney injury and chronic kidney disease in the intensive care unit.

To describe the epidemiology of acute kidney injury, its relationship to chronic kidney disease, and the factors associated with its incidence.

Does elastin deficiency cause chronic kidney disease?

Elastin deficiency in aging and disease is linked to increased vascular stiffness and hypertension, which are both associated with chronic kidney disease. Owens et al. show that alterations in renal arteries and kidney structure precede or are independent of hypertension in elastin haploinsufficient mice. This commentary addresses the authors' findings in light of the relationships between elastin amounts, vascular stiffness, and pressure wave reflection and transmission in the kidney vasculature.

Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease.

Sarcopenia, the age-related loss of muscle mass and function, frequently accompanies chronic kidney disease. The aim of this study was to clarify the prevalence and the risk factors for sarcopenia among patients with non-dialysis-dependent chronic kidney disease (NDD-CKD), focusing on the use of drugs.

High Phosphate-Induced Calcification of Vascular Smooth Muscle Cells is Associated with the TLR4/NF-κb Signaling Pathway.

Hyperphosphatemia is one of the most notable features of chronic kidney disease (CKD). Numerous epidemiological and clinical studies have found that high serum phosphate concentrations are associated with calcification in the coronary arteries. However, the mechanisms underlying the vascular calcification induced by high phosphate have not been understood fully.

Long-term patient and kidney survival after coronary artery bypass grafting, percutaneous coronary intervention, or medical therapy for patients with chronic kidney disease: a propensity-matched cohort study.

Revascularization in patients with chronic kidney disease (CKD) and coronary artery disease (CAD) is often deferred because of concern over progression of renal failure.

Chronic kidney disease and metabolic syndrome as risk factors for cardiovascular disease in a primary care program.

Cardiovascular disease (CVD) is especially prevalent in patients with chronic kidney disease (CKD).

Quick Search